VANCOUVER, British Columbia — February 18, 2026 — Leads & Copy — NervGen Pharma Corp. (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company, announced that its President and CEO, Adam Rogers, MD, along with other executive leadership team members, will participate in several upcoming investor conferences.
NervGen is focused on developing neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions.
The conferences include:
Oppenheimer 36th Annual Healthcare Life Sciences Conference, February 25-26, 2026:
Format: Corporate Presentation and 1×1 Investor Meetings
Presentation Date: Wednesday, February 25th
Time: 12:40 – 1:10 pm ET
Location: Virtual
TD Cowen 46th Annual Health Care Conference, March 2-4, 2026:
Format: Corporate Presentation and 1×1 Investor Meetings
Presentation Date: Monday, March 2nd
Time: 2:30 – 3:00 pm ET
Location: Boston, MA
Leerink Partners Global Healthcare Conference, March 8-11, 2026:
Format: 1×1 Investor Meetings
Location: Miami, FL
A live webcast and archived replay of the presentations will be available on the investors section of www.nervgen.com.
NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. It was evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI between 1 to 10 years post-injury and is the first pharmacologic candidate to demonstrate durable improvement in function, independence, and quality of life.
The Company’s Phase 1b/2a CONNECT SCI Study in individuals with subacute SCI is ongoing, alongside preparation for a Phase 3 clinical trial in chronic SCI. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.
Source: NervGen Pharma
